3 results
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…
The RAFT study addresses the added value of resynchronization therapy (CRT) in heart failure patients with an ICD indication and optimal pharmacological treatment. Will this result in lower mortality and less hospitalization? Results of the study…